Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder Psychedelics Investing
SVN-SDN-14 PTSD Programme - Positive pre-clinical results with three high-performing candidates advancing to in vivo studies Biotech Investing
Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA Life Science Investing
Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights Life Science Investing
Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025 Life Science Investing
Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET Life Science Investing
